Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Non-Current Liabilities: 2011-2024

Historic Total Non-Current Liabilities for RedHill Biopharma (RDHL) over the last 14 years, with Dec 2024 value amounting to $503,000.

  • RedHill Biopharma's Total Non-Current Liabilities fell 31.51% to $500,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $500,000, marking a year-over-year decrease of 31.51%. This contributed to the annual value of $503,000 for FY2024, which is 49.45% down from last year.
  • As of FY2024, RedHill Biopharma's Total Non-Current Liabilities stood at $503,000, which was down 49.45% from $995,000 recorded in FY2023.
  • In the past 5 years, RedHill Biopharma's Total Non-Current Liabilities registered a high of $93.1 million during FY2020, and its lowest value of $503,000 during FY2024.
  • For the 3-year period, RedHill Biopharma's Total Non-Current Liabilities averaged around $3.8 million, with its median value being $995,000 (2023).
  • Per our database at Business Quant, RedHill Biopharma's Total Non-Current Liabilities spiked by 2,575.73% in 2020 and then slumped by 89.86% in 2023.
  • Yearly analysis of 5 years shows RedHill Biopharma's Total Non-Current Liabilities stood at $93.1 million in 2020, then dropped by 2.47% to $90.8 million in 2021, then plummeted by 89.19% to $9.8 million in 2022, then plummeted by 89.86% to $995,000 in 2023, then slumped by 49.45% to $503,000 in 2024.